Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Olive

Showing results (21-30 of 276) with videos related to

Pageof 28
Sort By:
Current Molecular Medicine|October 29, 2009
Cosignaling molecules around LIGHT-HVEM-BTLA: from immune activation to therapeutic targetingChristine Pasero, Alemseged Truneh, Daniel Olive
Frontiers in Immunology|November 3, 2022
Major pathways involved in macrophage polarization in cancerClément Kerneur, Carla E Cano, Daniel Olive
Frontiers in Immunology|July 3, 2020
Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of CancerLoredana Cifaldi, James Di Santo, Daniel Olive
Oncoimmunology|November 19, 2013
BTLA, a key regulator of Vγ9Vδ2 T-cell proliferationJulie Gertner-Dardenne, Cyril Fauriat, Daniel Olive
Discovery Medicine|August 14, 2010
Natural killer cells and immunity against cancerRegis T Costello, Cyril Fauriat, Daniel Olive
Immunity|April 18, 2019
An X-ray Vision for Phosphoantigen RecognitionMichael L Dustin, Emmanuel Scotet, Daniel Olive
Autoimmunity|October 23, 2002
Costimulatory molecules and autoimmune thyroid diseasesClaudia Salmaso, Daniel Olive, Giampaola Pesce, et al.
Trends in Immunology|July 16, 2003
A co-evolution perspective of the TNFSF and TNFRSF families in the immune systemYves Collette, André Gilles, Pierre Pontarotti, et al.
Trends in Molecular Medicine|August 10, 2005
Imatinib: the narrow line between immune tolerance and activationMohamad Mohty, Didier Blaise, Daniel Olive, et al.
Cancers|July 2, 2021
Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized MiceNicolas Aubert, Simon Brunel, Daniel Olive, et al.
Pageof 28

Showing results (21-30 of 276) with videos related to

Sort By:
Pageof 28
Current Molecular Medicine|October 29, 2009
Cosignaling molecules around LIGHT-HVEM-BTLA: from immune activation to therapeutic targetingChristine Pasero, Alemseged Truneh, Daniel Olive
Frontiers in Immunology|November 3, 2022
Major pathways involved in macrophage polarization in cancerClément Kerneur, Carla E Cano, Daniel Olive
Frontiers in Immunology|July 3, 2020
Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of CancerLoredana Cifaldi, James Di Santo, Daniel Olive
Oncoimmunology|November 19, 2013
BTLA, a key regulator of Vγ9Vδ2 T-cell proliferationJulie Gertner-Dardenne, Cyril Fauriat, Daniel Olive
Discovery Medicine|August 14, 2010
Natural killer cells and immunity against cancerRegis T Costello, Cyril Fauriat, Daniel Olive
Immunity|April 18, 2019
An X-ray Vision for Phosphoantigen RecognitionMichael L Dustin, Emmanuel Scotet, Daniel Olive
Autoimmunity|October 23, 2002
Costimulatory molecules and autoimmune thyroid diseasesClaudia Salmaso, Daniel Olive, Giampaola Pesce, et al.
Trends in Immunology|July 16, 2003
A co-evolution perspective of the TNFSF and TNFRSF families in the immune systemYves Collette, André Gilles, Pierre Pontarotti, et al.
Trends in Molecular Medicine|August 10, 2005
Imatinib: the narrow line between immune tolerance and activationMohamad Mohty, Didier Blaise, Daniel Olive, et al.
Cancers|July 2, 2021
Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized MiceNicolas Aubert, Simon Brunel, Daniel Olive, et al.
Pageof 28